Functional Natural Killer-cell Genetics and Microvascular Inflammation After Kidney Transplantation: An Observational Cohort Study.
Journal
Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144
Informations de publication
Date de publication:
15 Oct 2024
15 Oct 2024
Historique:
medline:
15
10
2024
pubmed:
15
10
2024
entrez:
15
10
2024
Statut:
aheadofprint
Résumé
Recent evidence highlights the pivotal role of natural killer (NK) cells in allograft rejection. We explored associations of missing self and gene polymorphisms determining the phenotype and/or functionality of NK cells with microvascular inflammation (MVI) in a single-center cohort of 507 consecutive kidney transplant recipients. Patients were genotyped for killer cell Ig-like receptors and polymorphisms in 4 selected genes (FCGR3AV/F158 [rs396991], KLRC2wt/del, KLRK1HNK/LNK [rs1049174], and rs9916629-C/T). MVI was detected in 69 patients (13.6%). In a proportional odds model, the KLRC2del/del variant reduced MVI risk (odds ratio [OR] 0.26; 95% confidence interval [CI], 0.05-0.93; P = 0.037) independent of donor-specific antibodies, HLA class II eplet mismatch, and number of biopsies. Conversely, missing self (OR 1.40; 95% CI, 1.08-1.80; P = 0.011) and the rs9916629 T/T gene variant increased the risk (OR 1.70; 95% CI, 1.08-2.68; P = 0.021). Graft loss tended to be more frequent among patients with missing self ≥2 (hazard ratio 1.97; 95% CI, 0.89-4.37; P = 0.097), without influence on estimated glomerular filtration trajectories. FCGR3A variants were associated with MVI only in patients with preformed and/or de novo donor-specific antibodies (OR 4.14; 95% CI, 0.99-17.47; P = 0.052). Missing self and NK-cell genetics may contribute to MVI, underscoring the important role of NK cells in transplant rejection.
Sections du résumé
BACKGROUND
BACKGROUND
Recent evidence highlights the pivotal role of natural killer (NK) cells in allograft rejection.
METHODS
METHODS
We explored associations of missing self and gene polymorphisms determining the phenotype and/or functionality of NK cells with microvascular inflammation (MVI) in a single-center cohort of 507 consecutive kidney transplant recipients. Patients were genotyped for killer cell Ig-like receptors and polymorphisms in 4 selected genes (FCGR3AV/F158 [rs396991], KLRC2wt/del, KLRK1HNK/LNK [rs1049174], and rs9916629-C/T).
RESULTS
RESULTS
MVI was detected in 69 patients (13.6%). In a proportional odds model, the KLRC2del/del variant reduced MVI risk (odds ratio [OR] 0.26; 95% confidence interval [CI], 0.05-0.93; P = 0.037) independent of donor-specific antibodies, HLA class II eplet mismatch, and number of biopsies. Conversely, missing self (OR 1.40; 95% CI, 1.08-1.80; P = 0.011) and the rs9916629 T/T gene variant increased the risk (OR 1.70; 95% CI, 1.08-2.68; P = 0.021). Graft loss tended to be more frequent among patients with missing self ≥2 (hazard ratio 1.97; 95% CI, 0.89-4.37; P = 0.097), without influence on estimated glomerular filtration trajectories. FCGR3A variants were associated with MVI only in patients with preformed and/or de novo donor-specific antibodies (OR 4.14; 95% CI, 0.99-17.47; P = 0.052).
CONCLUSIONS
CONCLUSIONS
Missing self and NK-cell genetics may contribute to MVI, underscoring the important role of NK cells in transplant rejection.
Identifiants
pubmed: 39402708
doi: 10.1097/TP.0000000000005228
pii: 00007890-990000000-00897
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Sellarés J, de Freitas DG, Mengel M, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant. 2012;12:388–399.
Mayrdorfer M, Liefeldt L, Wu K, et al. Exploring the complexity of death-censored kidney allograft failure. J Am Soc Nephrol. 2021;32:1513–1526.
Naesens M, Roufosse C, Haas M, et al. The Banff 2022 Kidney Meeting Report: reappraisal of microvascular inflammation and the role of biopsy-based transcript diagnostics. Am J Transplant. 2023;24:338–349.
Callemeyn J, Lerut E, de Loor H, et al. Transcriptional changes in kidney allografts with histology of antibody-mediated rejection without anti-HLA donor-specific antibodies. J Am Soc Nephrol. 2020;31:2168–2183.
Halloran PF, Madill-Thomsen KS, Pon S, et al.; INTERCOMEX Investigators. Molecular diagnosis of ABMR with or without donor-specific antibody in kidney transplant biopsies: differences in timing and intensity but similar mechanisms and outcomes. Am J Transplant. 2022;22:1976–1991.
Hidalgo LG, Sis B, Sellares J, et al. NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection. Am J Transplant. 2010;10:1812–1822.
Sablik KA, Litjens NHR, Klepper M, et al. Increased CD16 expression on NK cells is indicative of antibody-dependent cell-mediated cytotoxicity in chronic-active antibody-mediated rejection. Transpl Immunol. 2019;54:52–58.
Yazdani S, Callemeyn J, Gazut S, et al. Natural killer cell infiltration is discriminative for antibody-mediated rejection and predicts outcome after kidney transplantation. Kidney Int. 2019;95:188–198.
Hirohashi T, Chase CM, Della Pelle P, et al. A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am J Transplant. 2012;12:313–321.
Lamarthée B, Callemeyn J, Van Herck Y, et al. Transcriptional and spatial profiling of the kidney allograft unravels a central role for FcyRIII+ innate immune cells in rejection. Nat Commun. 2023;14:1–22.
Mayer KA, Schrezenmeier E, Diebold M, et al. A randomized phase 2 trial of felzartamab in antibody-mediated rejection. N Engl J Med. 2024;391:122–132.
Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol. 2008;9:495–502.
Callemeyn J, Senev A, Coemans M, et al. Missing self-induced microvascular rejection of kidney allografts: a population-based study. J Am Soc Nephrol. 2021;32:2070–2082.
Koenig A, Chen CC, Marçais A, et al. Missing self triggers NK cell-mediated chronic vascular rejection of solid organ transplants. Nat Commun. 2019;10:5350.
Venner JM, Hidalgo LG, Famulski KS, et al. The molecular landscape of antibody-mediated kidney transplant rejection: evidence for NK involvement through CD16a Fc receptors. Am J Transplant. 2015;15:1336–1348.
Arnold ML, Kainz A, Hidalgo LG, et al. Functional Fc gamma receptor gene polymorphisms and donor-specific antibody-triggered microcirculation inflammation. Am J Transplant. 2018;18:2261–2273.
Delpire B, Van Loon E, Naesens M. The role of Fc gamma receptors in antibody-mediated rejection of kidney transplants. Transpl Int. 2022;35:10465.
Litjens N, Peeters A, Gestel JK van, et al. The FCGR3A 158 V/V-genotype is associated with decreased survival of renal allografts with chronic active antibody-mediated rejection. Sci Rep. 2021;11:7903.
Buxeda A, Llinàs-Mallol L, Gimeno J, et al. Microvascular inflammation in the absence of human leukocyte antigen-donor-specific antibody and C4d: an orphan category in Banff classification with cytotoxic T and natural killer cell infiltration. Am J Transplant. 2023;23:464–474.
Wahrmann M, Döhler B, Arnold ML, et al. Functional Fc gamma receptor gene polymorphisms and long-term kidney allograft survival. Front Immunol. 2021;12:724331.
Moraru M, Cañizares M, Muntasell A, et al. Assessment of copy-number variation in the NKG2C receptor gene in a single-tube and characterization of a reference cell panel, using standard polymerase chain reaction. Tissue Antigens. 2012;80:184–187.
Muntasell A, López-Montañés M, Vera A, et al. NKG2C zygosity influences CD94/NKG2C receptor function and the NK-cell compartment redistribution in response to human cytomegalovirus. Eur J Immunol. 2013;43:3268–3278.
Muntasell A, Pupuleku A, Cisneros E, et al. Relationship of NKG2C copy number with the distribution of distinct cytomegalovirus-induced adaptive NK cell subsets. J Immunol. 2016;196:3818–3827.
Vietzen H, Döhler B, Tran TH, et al. Deletion of the natural killer cell receptor NKG2C encoding KLR2C gene and kidney transplant outcome. Front Immunol. 2022;13:829228.
Diebold M, Vietzen H, Heinzel A, et al. Natural killer cell functional genetics and donor-specific antibody-triggered microvascular inflammation. Am J Transplant. 2023;24:743–754.
Suárez-Alvarez B, López-Vázquez A, Baltar JM, et al. Potential role of NKG2D and its ligands in organ transplantation: new target for immunointervention. Am J Transplant. 2009;9:251–257.
Hayashi T, Imai K, Morishita Y, et al. Identification of the NKG2D haplotypes associated with natural cytotoxic activity of peripheral blood lymphocytes and cancer immunosurveillance. Cancer Res. 2006;66:563–570.
Xia Z, Liu Q, Berger CT, et al. A 17q12 allele is associated with altered NK cell subsets and function. J Immunol. 2012;188:3315–3322.
Hirt-Minkowski P, Handschin J, Stampf S, et al. Randomized trial to assess the clinical utility of renal allograft monitoring by urine CXCL10 chemokine. J Am Soc Nephrol. 2023;34:1456–1469.
Loupy A, Haas M, Roufosse C, et al. The Banff 2019 Kidney Meeting Report (I): updates on and clarification of criteria for T cell- and antibody-mediated rejection. Am J Transplant. 2020;20:2318–2331.
Amico P, Hirt-Minkowski P, Hönger G, et al. Risk stratification by the virtual crossmatch: a prospective study in 233 renal transplantations. Transpl Int. 2011;24:560–569.
Bielmann D, Hönger G, Lutz D, et al. Pretransplant risk assessment in renal allograft recipients using virtual crossmatching. Am J Transplant. 2007;7:626–632.
Vietzen H, Furlano PL, Traugott M, et al. The natural killer cell-associated rs9916629-C allele is a novel genetic risk factor for fatal COVID-19. J Med Virol. 2023;95:e28404.
Kreijveld E, van der Meer A, Tijssen HJ, et al. KIR gene and KIR ligand analysis to predict graft rejection after renal transplantation. Transplantation. 2007;84:1045–1051.
Tran TH, Unterrainer C, Fiedler G, et al. No impact of KIR-ligand mismatch on allograft outcome in HLA-compatible kidney transplantation. Am J Transplant. 2013;13:1063–1068.
van Bergen J, Thompson A, Haasnoot GW, et al. KIR-ligand mismatches are associated with reduced long-term graft survival in HLA-compatible kidney transplantation. Am J Transplant. 2011;11:1959–1964.
Littera R, Piredda G, Argiolas D, et al. KIR and their HLA Class I ligands: two more pieces towards completing the puzzle of chronic rejection and graft loss in kidney transplantation. PLoS One. 2017;12:e0180831.
Callemeyn J, Lamarthée B, Koenig A, et al. Allorecognition and the spectrum of kidney transplant rejection. Kidney Int. 2022;101:692–710.
Senev A, Coemans M, Lerut E, et al. Histological picture of antibody-mediated rejection without donor-specific anti-HLA antibodies: clinical presentation and implications for outcome. Am J Transplant. 2019;19:763–780.
Lebraud E, Eloudzeri M, Rabant M, et al. Microvascular inflammation of the renal allograft: a reappraisal of the underlying mechanisms. Front Immunol. 2022;13:864730.
Vietzen H, Zoufaly A, Traugott M, et al. Deletion of the NKG2C receptor encoding KLRC2 gene and HLA-E variants are risk factors for severe COVID-19. Genet Med. 2021;23:963–967.
Hariharan S, Israni AK, Danovitch G. Long-Term survival after kidney transplantation. N Engl J Med. 2021;385:729–743.
Gelman A, Hill J. Data Analysis Using Regression and Multilevel/Hierarchical Models. Cambridge University Press; 2018.
Chen B, Cole JW, Grond-Ginsbach C. Departure from Hardy Weinberg equilibrium and genotyping error. Front Genet. 2017;8:167.
Gonzalez-Galarza FF, McCabe A, Santos EJMD, et al. Allele frequency net database (AFND) 2020 update: gold-standard data classification, open access genotype data and new query tools. Nucleic Acids Res. 2020;48:D783–D788.